Published in JAMA Dermatology
Importance Vitiligo can have profound effects on patients and is often associated with other autoimmune comorbid conditions. It is important to understand the current prevalence of vitiligo, including diagnosed, undiagnosed, and subtypes (nonsegmental and segmental). Objective To estimate the point prevalence of vitiligo in the US. Design, Setting,...
Published in JAMA Dermatology
Importance Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept. Objective To determine whether costimulatory signaling blockade with abatacept prevents psoriasis relapse after ustekinumab withdrawal. Design, Setting, and Participants Psoriasis Treatment with Abatacept and U...
Published in JAMA dermatology
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement. To assess the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD. Heads Up was a 24-week, head-to-head, phase 3b, multicenter, rando...
Published in JAMA Dermatology
This randomized clinical trial examines the efficacy and safety of abrocitinib plus topical therapy in adolescents with moderate-to-severe atopic dermatitis.
Published in JAMA Dermatology
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options. Objective To evaluate the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin 17A and 17F in individuals with moderate to severe HS. Design, Setting, an...
Published in JAMA dermatology
Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy studies, BREEZE-AD1 and BREEZE-AD2. Long-term efficacy has not yet been examined. To evaluate the long-term (68-week) efficacy of baricitinib in adults with moderate to severe at...
Published in JAMA dermatology
The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars. To assess the outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients wi...
Published in JAMA dermatology
Although limited effective and affordable treatment options exist for hidradenitis suppurativa, recent studies describe the effectiveness of a medical therapy, infliximab, for the treatment of hidradenitis suppurativa. Cost-saving biosimilar alternatives have recently become available, but no data currently exist on their safety and effectiveness. ...
Published in JAMA dermatology
Cutaneous immune-related adverse events (cirAEs) are some of the earliest toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early indicator of robust inflammatory response, cirAEs may be associated with patterns of immune-mediated toxic effects, but associations between these events and noncutaneous immune-rela...
Published in JAMA dermatology
Topical calcineurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis. In 2006, the US Food and Drug Administration issued a black box warning against TCI use, citing data from case reports and animal studies indicating a potential risk of cancer. To evaluate the association between TCI use and risk of malignant neo...
